Ney Carter Borges: Syphilis and Cardiovascular Risk – A Silent and Progressive Vascular Burden
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Eli Tsakiris et al., published in JAMA Network Open:
“Syphilis and Cardiovascular Risk: A Silent and Progressive Vascular Burden
A large cohort study published in JAMA Network Open invites a shift in how we think about syphilis.
Rather than a disease limited to its infectious phase, it appears to behave – over time – as a silent and progressive vascular condition.
Following 8,814 individuals for nearly 15 years (including 1,469 with syphilis), the study shows a clear and clinically meaningful pattern: patients with syphilis face a higher burden of cardiovascular events.
The risk of aortic aneurysm or dissection was more than doubled (HR 2.08; 95% CI, 1.47–2.94).
Stroke risk was also significantly elevated, both ischemic (HR 1.53; 95% CI, 1.27–1.84) and hemorrhagic (HR 1.92; 95% CI, 1.23–2.99).
Myocardial infarction increased by about one-third (HR 1.33; 95% CI, 1.06–1.67), and peripheral artery disease followed a similar pattern (HR 1.28; 95% CI, 1.01–1.62).
What stands out most is the broader impact: overall mortality was nearly six times higher in individuals with syphilis (HR 5.80; 95% CI, 3.81–8.82).
This is not a subtle signal – it reflects a systemic process unfolding over years.
Yet, the story is not uniform.
In early stages, syphilis did not significantly increase cardiovascular risk.
The burden emerges later, suggesting a slow, cumulative vascular injury.
The underlying mechanism is biologically coherent: Treponema pallidum induces chronic inflammation, particularly targeting the small vessels that nourish arterial walls (vasa vasorum), leading to weakening, remodeling, and eventually serious complications like aneurysm or stroke.
From a clinical perspective, the message is straightforward but powerful: timing changes outcomes.
Detecting and treating syphilis early may not only control infection but also prevent long-term vascular damage.
Even acknowledging the observational nature of the data, the consistency and magnitude of these findings support a more vigilant cardiovascular approach in patients with a history of syphilis.”
Title: Adverse Cardiovascular Outcomes in Patients With Syphilis
Authors: Eli Tsakiris, Han Feng, Ghassan Bidaoui, Christian Massad, Janice Zha, Zhihao Wu, Yishi Jia, Yingshuo Liu, Hadi Younes, Yara Menassa, Michel Abou Khalil, Mayana Bsoul, Mohammad Montaser Atasi, Samer Zakhour, David Mushatt, Omar Kreidieh, Nassir F Marrouche, Amitabh C Pandey
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Apr 22, 2026, 14:48Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly But the Right Test Will Hear It
-
Apr 22, 2026, 14:47Karuna Kumar: Busting the Myth about Increasing Infection Risk by IV Iron
-
Apr 22, 2026, 14:46David Brown: Charting a New Path Forward for One Patient Facing Extraordinary Cardiac Challenges
-
Apr 22, 2026, 14:44Sanjay Ahuja – New CEO and Medical Director of Innovative Hematology
-
Apr 22, 2026, 14:36Shivanand Kumatagi: Building Clinical Research Skills at the ASH CRTI Asia Pacific Program
-
Apr 22, 2026, 14:22Pradeep Natarajan: Can Polygenic Risk Scores Refine Risk Stratification in Secondary Prevention of CAD
-
Apr 22, 2026, 14:16Omar Adwan: Rare Genetic Disorders of Red Blood Cell Membrane Abnormalities
-
Apr 22, 2026, 14:10Alan Nurden: Pregnancy Challenges and Bleeding Risks in Inherited Platelet Disorders
-
Apr 22, 2026, 12:57Ali AlBahar: DNA Drives the Molecular Era of Blood Typing